AbbVie looks to "restore integrity" to the 340B program with its suit, it explained in its 72-page filing. (iStock / Getty Images Plus) AbbVie is spearheading a new battle in pharma’s long-running ...
The 340B Drug Pricing Program was designed to help safety net providers serve low-income patients, but it has since ballooned into a multibillion-dollar system dominated by large health systems — with ...
This approach would aim to raise the same amount of revenue that was previously generated by covered entities’ arbitrage of 340B drugs without the perverse incentives perpetuated by the current ...
On March 17, 2026, the Ninth Circuit issued a unanimous decision in United States ex rel. Adventist Health Sys. of W. v. AbbVie Inc. allowing a large health system to pursue a False Claims Act (FCA) ...
The 340B Drug Pricing Program was created in 1992 to increase access to hospital outpatient medications for low‐income and uninsured patients by allowing covered entities that serve these patients to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results